Cellenkos is a series b startup based in United States. 1 investor tracked.
Cellenkos is a company founded in 2017 headquartered in the United States. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
Cellenkos is a clinical-stage biotechnology company focused on developing and commercializing novel T-regulatory (Treg) cell therapies to treat autoimmune and inflammatory disorders.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.